Farmacogenômica e a diversidade genética da população brasileira

Abstract

Brazilians represent one of the most heterogeneous populations in the world, as a result of five centuries of admixture between its three ancestral roots: autochthonous Amerindians, white Europeans, and sub-Saharan Africans. The heterogeneity and admixture of Brazilians has important implications for the design and interpretation of clinical trials, the implementation of pharmacogenetics/-genomics (PGx) knowledge in drug prescription, and the extrapolation of PGx data from other, more homogeneous populations. The population paradigm in PGx emerges from the observation that the frequency of several polymorphisms in "pharmacogenes" may vary widely among populations. One extreme example is provided by the CYP3A5 gene, which encodes the drug-metabolizing enzyme CYP3A5, important for the elimination of several clinically useful drugs, such as the immunosuppressants tacrolimus and cyclosporine. The frequency of the variant CYP3A5*3 allele, which encodes a non-functional CYP3A5 isoform, is less than 10% among sub-Saharan Africans but exceeds 90% among Europeans. However, the frequency of CYP3A5*3 in healthy Brazilians living in Rio de Janeiro, self-identified as white ("branco") or black ("preto") according to the "color/race" categorization of the Brazilian census, was 78% and 32%, respectively (Pharmacogenomics 2007; 8:1299-306). Thus, the CYP3A5*3 allele is three times more frequent among self-identified black Brazilians (32%) than black Africans (< 10%) and is considerably less common among self-identified white Brazilians (78%) than Europeans (> 95%). The African-European admixture of Brazilians provides an explanation for these discrepancies, since irrespective of "color/race" self-identification, most Brazilians share European and African genetic ancestries, and many have also a significant proportion of Amerindian ancestry (Pharmacogenomics in Admixed Populations. Landes Bioscience; 2007). It is reasonable to think that the sizeable contribution of European ancestry in self-identified black Brazilians accounts for the higher frequency of CYP3A5*3 in this group, compared to black Africans. Similarly, the proportion of African ancestry in white Brazilians may account for the lower frequency of CYP3A5*3 in the latter, compared to Europeans. The situation described for the CYP3A5*3 polymorphism was reproduced in our studies on other PGx polymorphisms (Pharmacogenet Genomics 2007; 17:765-72; Eur J Clin Pharmacol 2008; 3:253-6). Collectively, these results indicate that extrapolation of PGx data from relatively homogeneous groups (e.g. white Europeans or North Americans) is clearly not applicable to the majority of Brazilians (Trends Pharmacol Sci 2005; 26:196-201).Recognition of this fact prompted the creation of the Brazilian Pharmacogenetics Network (REFARGEN; http://www.refargen.org.br), a consortium of 18 research groups from Brazilian institutions, with the mission to provide leadership in PGx research and education in Brazil, with a population health impact. REFARGEN researchers developed logistic regression ...

Furosemide is associated with acute kidney injury in critically ill patients

“…The non-furosemide group had a greater proportion of Afrodescendents compared to the furosemide group. This difference can be a reflex of the difficulty to establish ethnicity in a highly miscegenated population such as the Brazilian one (15). MAP was lower in the furosemide group compared to the non-furosemide group but sufficient to maintain good kidney perfusion.…”

Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin

“…Recognition of this fact has prompted the creation of the Brazilian Pharmacogenomics Network or Refargen (Suarez-Kurtz, 2004), a nationwide consortium of research groups, mostly from academia 1 . In consonance with its mission to provide leadership in PGx research and education in Brazil, with impact on population heath (Suarez-Kurtz, 2009), Refargen has recently concluded a comprehensive study of the distribution of PGx polymorphisms among Brazilians. In this article, we will present original data and review previously published results (Suarez-Kurtz et al, 2010, 2012a,b,c; Pena et al, 2011; Sortica et al, 2012) from the Refargen study and discuss the PGx implications of the findings for Brazilians and possibly other admixed populations of the Americas.…”

Genetic Variants Involved in One-Carbon Metabolism: Polymorphism Frequencies and Differences in Homocysteine Concentrations in the Folic Acid Fortification Era

“…Some researchers criticize the use and limitations of self-declared race and consider the use of individual genetic ancestry to be the best measure of racial differences in genetic variations [34]. Nevertheless, significant differences in the prevalence of polymorphisms among self-declared races were observed, suggesting the importance of population miscegenation [35]. Therefore, the race variable must be considered in future population studies evaluating potential differences in serum concentrations of folate, homocysteine, B vitamins, and other molecules, consistent with previous studies [36,37].…”